AMP01 / Reverb Therapeutics - LARVOL DELTA

Quantitative Systems Pharmacology (QSP) enables research and translation of AMP01, a novel next generation anti PD1 bispecific that amplifies and redirects endogenous IL15 to PD1 high expressing T Cells, maximizing efficacy and therapeutic index (AACR 2026) - "The model accelerated the design and selection of AMP01, a potentially best in class next-generation multi-functional anti-PD1 therapy and provided insights into the complexity of IL15 mediated immune cell dynamics to better understand safety and efficacy for simulated virtual patient variability."

Bispecific • Clinical • First-in-human • IO biomarker • Late-breaking abstract • Hematological Malignancies • Oncology • IL15